{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:45:06Z","timestamp":1793051106690,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Key Research and Development Program of Jining City","award":["2024YXNS150"],"award-info":[{"award-number":["2024YXNS150"]}]},{"name":"The Natural Science Foundation of Fujian Province","award":["2024J011122"],"award-info":[{"award-number":["2024J011122"]}]},{"name":"the Science and Technology Commission of Pudong New Area Foundation","award":["[PKJ2022-Y02]"],"award-info":[{"award-number":["[PKJ2022-Y02]"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11010-025-05347-3","type":"journal-article","created":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T08:42:48Z","timestamp":1752396168000},"page":"5779-5791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CAR19-T\/NK cell and circular aptamer\u2013drug conjugate (ApDC) combination treatment increases immunotherapy efficacy"],"prefix":"10.1007","volume":"480","author":[{"given":"Ling-Qi","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Xuan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,13]]},"reference":[{"key":"5347_CR1","doi-asserted-by":"crossref","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X et al (2022) CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol 13:927153","journal-title":"Front Immunol"},{"issue":"9","key":"5347_CR2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12032-023-02146-y","volume":"40","author":"P Dabas","year":"2023","unstructured":"Dabas P, Danda A (2023) Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy. Med Oncol 40(9):275","journal-title":"Med Oncol"},{"issue":"1","key":"5347_CR3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00005-023-00684-x","volume":"71","author":"Y Cao","year":"2023","unstructured":"Cao Y et al (2023) Updated clinical perspectives and challenges of chimeric antigen receptor-T Cell therapy in colorectal cancer and invasive breast cancer. Arch Immunol Ther Exp (Warsz) 71(1):19","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"7","key":"5347_CR4","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1002\/cam4.5551","volume":"12","author":"S Abbasi","year":"2023","unstructured":"Abbasi S et al (2023) Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies. Cancer Med 12(7):7844\u20137858","journal-title":"Cancer Med"},{"issue":"3","key":"5347_CR5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/cancers15030663","volume":"15","author":"YJ Chen","year":"2023","unstructured":"Chen YJ, Abila B, Mostafa Kamel Y (2023) CAR-T: what is next? Cancers 15(3):663","journal-title":"Cancers"},{"issue":"1","key":"5347_CR6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/ejh.14090","volume":"112","author":"R Ma","year":"2024","unstructured":"Ma R et al (2024) Enhanced efficacy of CD19\/CD22 bispecific CAR-T cells with EAAAK linker on B-cell malignancies. Eur J Haematol 112(1):64\u201374","journal-title":"Eur J Haematol"},{"issue":"1","key":"5347_CR7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41408-024-01105-8","volume":"14","author":"L Wang","year":"2024","unstructured":"Wang L et al (2024) Bispecific CAR-T cells targeting CD19\/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I\/II trial. Blood Cancer J 14(1):130","journal-title":"Blood Cancer J"},{"issue":"12","key":"5347_CR8","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E et al (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5(12):1282\u20131295","journal-title":"Cancer Discov"},{"key":"5347_CR9","doi-asserted-by":"crossref","unstructured":"Turtle, C.J., et al., Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med, 2016. 8(355): p. 355ra116","DOI":"10.1126\/scitranslmed.aaf8621"},{"issue":"10","key":"5347_CR10","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah NN et al (2020) Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med 26(10):1569\u20131575","journal-title":"Nat Med"},{"issue":"3","key":"5347_CR11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ (2020) Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17(3):147\u2013167","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"5347_CR12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H et al (2021) A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol 14(1):161","journal-title":"J Hematol Oncol"},{"issue":"14","key":"5347_CR13","first-page":"1632","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong C et al (2020) Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma. Blood 136(14):1632\u20131644","journal-title":"Blood"},{"key":"5347_CR14","doi-asserted-by":"crossref","unstructured":"Chen, Z., et al., Artificial intelligence in aptamer-target binding prediction. Int J Mol Sci, 2021. 22(7).","DOI":"10.3390\/ijms22073605"},{"key":"5347_CR15","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.omtn.2022.01.008","volume":"27","author":"BJ Thomas","year":"2022","unstructured":"Thomas BJ, Porciani D, Burke DH (2022) Cancer immunomodulation using bispecific aptamers. Mol Ther Nucleic Acids 27:894\u2013915","journal-title":"Mol Ther Nucleic Acids"},{"key":"5347_CR16","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.omtn.2023.08.015","volume":"33","author":"K Pleiko","year":"2023","unstructured":"Pleiko K et al (2023) Targeting triple-negative breast cancer cells with a \u03b21-integrin binding aptamer. Mol Ther Nucleic Acids 33:871\u2013884","journal-title":"Mol Ther Nucleic Acids"},{"issue":"22","key":"5347_CR17","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1021\/jacs.8b03442","volume":"140","author":"Y Jiang","year":"2018","unstructured":"Jiang Y et al (2018) Supramolecularly engineered circular bivalent aptamer for enhanced functional protein delivery. J Am Chem Soc 140(22):6780\u20136784","journal-title":"J Am Chem Soc"},{"issue":"5","key":"5347_CR18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1021\/acs.bioconjchem.4c00050","volume":"35","author":"T Abudureheman","year":"2024","unstructured":"Abudureheman T et al (2024) Construction of switch modules for CAR-T Cell treatment using a site-specific conjugation system. Bioconjug Chem 35(5):604\u2013615","journal-title":"Bioconjug Chem"},{"issue":"11","key":"5347_CR19","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1007\/s00262-023-03526-z","volume":"72","author":"WW Zheng","year":"2023","unstructured":"Zheng WW et al (2023) Anti-CD79b\/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment. Cancer Immunol Immunother 72(11):3739\u20133753","journal-title":"Cancer Immunol Immunother"},{"key":"5347_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.03.006","volume":"229","author":"K Heo","year":"2016","unstructured":"Heo K et al (2016) An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies. J Control Release 229:1\u20139","journal-title":"J Control Release"},{"key":"5347_CR21","doi-asserted-by":"crossref","first-page":"124722","DOI":"10.1016\/j.talanta.2023.124722","volume":"263","author":"LT Yang","year":"2023","unstructured":"Yang LT et al (2023) A novel His-tag-binding aptamer for recombinant protein detection and T cell-based immunotherapy. Talanta 263:124722","journal-title":"Talanta"},{"issue":"10","key":"5347_CR22","doi-asserted-by":"crossref","first-page":"e202200141","DOI":"10.1002\/open.202200141","volume":"11","author":"L Wu","year":"2022","unstructured":"Wu L et al (2022) Aptamer-based cancer cell analysis and treatment. ChemistryOpen 11(10):e202200141","journal-title":"ChemistryOpen"},{"issue":"4","key":"5347_CR23","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.apsb.2023.01.017","volume":"13","author":"J He","year":"2023","unstructured":"He J et al (2023) Recent progress of aptamer-drug conjugates in cancer therapy. Acta Pharm Sin B 13(4):1358\u20131370","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"5347_CR24","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.3390\/cancers15072010","volume":"15","author":"L Agnello","year":"2023","unstructured":"Agnello L et al (2023) Aptamer-Based Strategies to Boost Immunotherapy in TNBC. Cancers 15(7):2010","journal-title":"Cancers"},{"issue":"8","key":"5347_CR25","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3390\/ijms21082793","volume":"21","author":"Z Fu","year":"2020","unstructured":"Fu Z, Xiang J (2020) Aptamers, the nucleic acid antibodies, in cancer therapy. Int J Mol Sci 21(8):2793","journal-title":"Int J Mol Sci"},{"issue":"26","key":"5347_CR26","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/s41388-024-03060-x","volume":"43","author":"C Dessaux","year":"2024","unstructured":"Dessaux C et al (2024) Recent insights into the therapeutic strategies targeting the pseudokinase PTK7 in cancer. Oncogene 43(26):1973\u20131984","journal-title":"Oncogene"},{"issue":"4","key":"5347_CR27","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15960","volume":"186","author":"H Khogeer","year":"2019","unstructured":"Khogeer H et al (2019) Early T precursor acute lymphoblastic leukaemia\/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol 186(4):538\u2013548","journal-title":"Br J Haematol"},{"key":"5347_CR28","doi-asserted-by":"crossref","first-page":"665970","DOI":"10.3389\/fimmu.2021.665970","volume":"12","author":"Y Jie","year":"2021","unstructured":"Jie Y et al (2021) PTK7-targeting CAR T-Cells for the Treatment of lung cancer and other malignancies. Front Immunol 12:665970","journal-title":"Front Immunol"},{"issue":"3","key":"5347_CR29","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3390\/cancers15030922","volume":"15","author":"E Sicco","year":"2023","unstructured":"Sicco E et al (2023) Targeted-lymphoma drug delivery system based on the Sgc8-c aptamer. Cancers 15(3):922","journal-title":"Cancers"},{"issue":"4","key":"5347_CR30","first-page":"262","volume":"35","author":"E Sicco","year":"2020","unstructured":"Sicco E et al (2020) Sgc8-c aptamer as a potential theranostic agent for hemato-oncological malignancies. Cancer Biother Radiopharm 35(4):262\u2013270","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"5347_CR31","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41392-024-01973-3","volume":"9","author":"Y Xiao","year":"2024","unstructured":"Xiao Y et al (2024) Aptamer-drug conjugates-loaded bacteria for pancreatic cancer synergistic therapy. Signal Transduct Targ Ther 9(1):272","journal-title":"Signal Transduct Targ Ther"},{"issue":"1","key":"5347_CR32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/jacs.7b08518","volume":"140","author":"Y Wu","year":"2018","unstructured":"Wu Y et al (2018) Enhanced targeted gene transduction: AAV2 vectors conjugated to multiple aptamers via reducible disulfide linkages. J Am Chem Soc 140(1):2\u20135","journal-title":"J Am Chem Soc"},{"key":"5347_CR33","doi-asserted-by":"crossref","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X et al (2023) CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. Front Immunol 14:1101495","journal-title":"Front Immunol"},{"issue":"1","key":"5347_CR34","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40364-022-00434-9","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y et al (2022) Strategies to enhance CAR-T persistence. Biomark Res 10(1):86","journal-title":"Biomark Res"},{"key":"5347_CR35","doi-asserted-by":"crossref","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber D, Wang LD (2022) Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. EBioMedicine 77:103941","journal-title":"EBioMedicine"},{"issue":"1","key":"5347_CR36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12943-023-01894-9","volume":"22","author":"F Ramezani","year":"2023","unstructured":"Ramezani F et al (2023) Outsmarting trogocytosis to boost CAR NK\/T cell therapy. Mol Cancer 22(1):183","journal-title":"Mol Cancer"},{"key":"5347_CR37","doi-asserted-by":"crossref","first-page":"1166038","DOI":"10.3389\/fimmu.2023.1166038","volume":"14","author":"MK Kilgour","year":"2023","unstructured":"Kilgour MK et al (2023) Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy. Front Immunol 14:1166038","journal-title":"Front Immunol"},{"issue":"27","key":"5347_CR38","doi-asserted-by":"crossref","first-page":"9128","DOI":"10.1021\/jacs.7b04547","volume":"139","author":"H Kuai","year":"2017","unstructured":"Kuai H et al (2017) circular bivalent aptamers enable in vivo stability and recognition. J Am Chem Soc 139(27):9128\u20139131","journal-title":"J Am Chem Soc"},{"key":"5347_CR39","doi-asserted-by":"crossref","first-page":"115409","DOI":"10.1016\/j.ab.2023.115409","volume":"685","author":"Z Ma","year":"2024","unstructured":"Ma Z et al (2024) Characterization of an ssDNA ligase and its application in aptamer circularization. Anal Biochem 685:115409","journal-title":"Anal Biochem"},{"issue":"1","key":"5347_CR40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K et al (2022) CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res 41(1):119","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"5347_CR41","first-page":"813","volume":"10","author":"Q Zhang","year":"2024","unstructured":"Zhang Q et al (2024) Aptamer-based nongenetic reprogramming of CARs enables flexible modulation of T cell-mediated tumor immunotherapy. ACS Cent Sci 10(4):813\u2013822","journal-title":"ACS Cent Sci"},{"issue":"22","key":"5347_CR42","doi-asserted-by":"crossref","first-page":"e1900903","DOI":"10.1002\/smll.201900903","volume":"15","author":"S Yang","year":"2019","unstructured":"Yang S et al (2019) Aptamer-engineered natural killer cells for cell-specific adaptive immunotherapy. Small 15(22):e1900903","journal-title":"Small"},{"issue":"6","key":"5347_CR43","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1021\/acsptsci.1c00188","volume":"4","author":"B Maru","year":"2021","unstructured":"Maru B, Nadeau L, McKeague M (2021) Enhancing CAR-T Cell therapy with functional nucleic acids. ACS Pharmacol Transl Sci 4(6):1716\u20131727","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"6","key":"5347_CR44","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1002\/jcp.30197","volume":"236","author":"B Liang","year":"2021","unstructured":"Liang B et al (2021) Tumor-derived exosomes in the PD-1\/PD-L1 axis: Significant regulators as well as promising clinical targets. J Cell Physiol 236(6):4138\u20134151","journal-title":"J Cell Physiol"},{"issue":"4","key":"5347_CR45","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.3390\/ijms24044197","volume":"24","author":"K Cheng","year":"2023","unstructured":"Cheng K et al (2023) 4\u20131BB-Based CAR T cells effectively reverse exhaustion and enhance the anti-tumor immune response through autocrine PD-L1 scFv antibody. Int j mol sci 24(4):4197","journal-title":"Int j mol sci"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05347-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-025-05347-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05347-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:08:25Z","timestamp":1761750505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-025-05347-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,13]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["5347"],"URL":"https:\/\/doi.org\/10.1007\/s11010-025-05347-3","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,13]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors obtained written informed consent from all the participants for the publication of any potentially identifiable information, including images and data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}